Expected earnings - Arbutus Biopharma Corporation
Source: US Earnings Reports
Arbutus Biopharma Corporation (ABUS) is expected to report $-0.02 for Q2 2025
Arbutus Biopharma Corporation
NASDAQ: ABUS
ABUS Trading
-4.88% G/L:
$4.485 Last:
1,444,805 Volume:
$4.59 Open:
ABUS Latest News
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
November 13, 2025 07:30:00 am
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 07, 2025 08:00:00 am
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
ABUS Stock Data
$811,607,352
153,282,242
0.14%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Warminster
